Background: Multiple published quantitative systematic reviews have reported on adverse
events associated with the use of sodium glucose co-transporter 2 (SGLT-2) inhibitors in …

Abstract Sodium-glucose co-transporter 2 (SGLT2) inhibitors have a well-defined safety
profile based on data obtained from numerous clinical trials, including cardiovascular …

Objective To estimate the association between the use of sodium glucose co-transporter-2
(SGLT2) inhibitors and postmarket harms as identified by drug regulatory agencies. Design …

Sodium glucose co‐transporter 2 inhibitors (SGLT2is) are the first class of glucose lowering
agent to be shown to reduce cardiovascular events. They are generally well tolerated with …

Context SGLT2is are first-line antidiabetic agents with demonstrated cardiovascular benefits.
Prior meta-analyses have examined adverse events (AEs) associated with these drugs in …

In type 2 diabetes (T2DM), glycaemic control delays the development and slows the
progression of complications. Although there are numerous glucose-lowering agents in …

There are no relevant meta-analyses that have assessed the safety of the sodium-glucose
transporter 2 (SGLT2) inhibitors in different chronic diseases. We aimed at evaluating the …

Aims To evaluate the mid long-term efficacy and safety of sodium–glucose cotransporter 2
(SGLT2) inhibitors in adults with type 2 diabetes mellitus (T2DM). Methods Three databases …

Background: Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a new class of
antidiabetic drugs. Purpose: To assess the efficacy and safety of SGLT2 inhibitors in adults …

Introduction: Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are recommended
after metformin for a large spectrum of patients with type 2 diabetes, because of a favorable …